Human antibodies as next generation therapeutics

Current Opinion in Chemical Biology

Volumn 5, Issue 4, 2001, Pages 368-374

  Van Dijk, Marc A ^a   Van De Winkel, Jan G J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALEMTUZUMAB; EDRECOLOMAB; GEMTUZUMAB OZOGAMICIN; IMMUNOGLOBULIN A1; IMMUNOGLOBULIN A2; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; OKT 3; PALIVIZUMAB; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLERGY; AMINO ACID SEQUENCE; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; B LYMPHOCYTE; BLOOD CLOT; BREAST CARCINOMA; COLON CROHN DISEASE; COLORECTAL CANCER; FOOD AND DRUG ADMINISTRATION; GRAFT REJECTION; HUMAN; IMMUNOREACTIVITY; KIDNEY GRAFT REJECTION; LOWER RESPIRATORY TRACT INFECTION; LYMPHATIC LEUKEMIA; MOLECULAR EVOLUTION; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; RIBOSOME;

EID: 0035415661     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(00)00216-7     Document Type: Review

References (56)

1. Continuous cultures of fused cells secreting antibody of predefined specificity
2. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy
3. Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG
4. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
5. Signaling antibodies in cancer therapy
6. Trastuzumab and chemotherapeutics: Drug interactions and synergies
7. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
8. Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation
9. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody
10. A clinical trial of anti-idiotype therapy for B-cell malignancy
11. The efficient production of stable, human monoclonal antibody-secreting hybridomas from EBV-transformed lymphocytes using the mouse myeloma X63-Ag8.653 as a fusion partner
12. Production of human monoclonal IgG and IgM antibodies with anti-D (rhesus) specificity using heterohybridomas
13. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety
14. Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20
15. Prophylaxis with respiratory syncytial virus F-specific humanized monoclonal antibody delays and moderately suppresses the native antibody response but does not impair immunity to late rechallenge
16. Construction, expression and characterization of humanized antibodies directed against the human alpha/beta T-cell receptor
17. Humanization of an anti-p185HER2 antibody for human cancer therapy
18. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys
19. Creating and engineering human antibodies for immunotherapy
20. Human antibodies by design
21. Multi-subunit proteins on the surface of filamentous phage: Methodologies for displaying antibody (Fab) heavy and light chains
22. Panning phage antibody libraries on cells: Isolation of human Fab fragments against ovarian carcinoma using guided selection
23. Recombinant polyclonal antibody libraries
24. Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display
25. The Trimera mouse: Generating human monoclonal antibodies and an animal model for human diseases
26. Human/BALB radiation chimera engrafted with splenocytes from patients with idiopathic thrombocytopenic purpura produce human platelet antibodies
27. Human monoclonal antibodies specific to hepatitis B virus generated in a human/mouse radiation chimera: The Trimera system
28. Generating high-avidity human Mabs in mice
29. Fully human anti-interleukin-8 monoclonal antibodies: Potential therapeutics for the treatment of inflammatory disease states
30. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice
31. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies
32. Production of human antibody repertoires in transgenic mice
33. Class switching in human immunoglobulin transgenic mice
34. Human antibodies from transgenic mice
35. Human IgG Fc receptor heterogeneity: Molecular aspects and clinical implications
36. Monoclonal IgA antibodies protect against Acanthamoeba keratitis
37. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies
38. FcalphaRI-positive liver Kupffer cells: Reappraisal of the function of immunoglobulin α in immunity
39. IgA and the IgA Fc receptor
40. Double trans-chromosomic mice: Maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies
41. Manipulation of human minichromosomes to carry greater than megabase-sized chromosome inserts
42. GPIIb/IIIa antagonists: Pathophysiologic and therapeutic insights from studies of c7E3 Fab
43. Therapeutic antibody fragments with prolonged in vivo half-lives
44. Recombinant antibody constructs in cancer therapy
45. Technology evaluation: Gemtuzumab ozogamicin, Celltech group
46. The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma
47. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience
48. Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells
49. Glycosylation of the variable region of immunoglobulin G-site specific maturation of the sugar chains
50. Glycosylation of human IgG subclass and mouse IgG2b heavy chains secreted by mouse J558L transfectoma cell lines as chimeric antibodies
51. Transgenic milk as a method for the production of recombinant antibodies
52. Antibody production by molecular farming in plants
53. Production of antibodies in transgenic plants
54. Feasibility of antibody production in plants for human therapeutic use
55. N-Glycosylation of a mouse IgG expressed in transgenic tobacco plants
56. Galactose-extended glycans of antibodies produced by transgenic plants